NCT05617703

Brief Summary

The goal of this \[type of study: Randomized clinical trial\] to compare the clinical performance of using glass ionomer with advanced glass hybrid technology (AGH) in cervical carious lesion, versus Resin modified glass ionomer (RMGI) using esthetic and mechanical properties according to FDI criteria over one year. in adult patients with cervical carious lesion. The main question it aims to answer are: • Will the use of glass ionomer with advanced glass hybrid technology, achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass ,or Resin Modified Glass Ionomer have better mechanical and estheic properties over one year in adult patients with cervical carious lesions ? Participants will be assessed for medical and dental histories first. Then an examination of the patients will be done using visual inspection by using a dental mirror and probe. Eligible patients according to inclusion and exclusion criteria will be informed about all procedures with follow up time if they accept, their signature on written informed consents will be obtained. Eligible participants will be randomly divided into two groups according to the type of restoration that will be received after class V cavity preparations for carious cervical lesions. Patients will be given local anaesthesia (Mepecaine - L Cartridges) as required, and the teeth will be isolated. A No. #330 bur (MANI, INC, Japan) in a high-speed hand piece with air/water coolant will be used to prepare class V cavity. Sharp excavators of suitable size were used to excavate soft carious lesions in dentin. the prepared cavity will be isolated with rubber dam. The first group (A) will be received resin modified glass ionomer restorative material and the second group (B) will be received advanced glass hybrid glass ionomer . Each restoration will be evaluated for clinical parameters after finishing and polishing at baseline and regular recalls of 6 months and one year. The restorations will be clinically examined according to FDI criteria criteria in terms of esthetic and mechanical properties . The information that will be obtained will be collected and statistically analyzed.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 8, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 15, 2022

Completed
16 days until next milestone

Study Start

First participant enrolled

December 1, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

November 15, 2022

Status Verified

November 1, 2022

Enrollment Period

1 year

First QC Date

November 8, 2022

Last Update Submit

November 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • FDI criteria

    Esthetic and mechanical evaluation

    one year

Study Arms (2)

Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)

EXPERIMENTAL

Glass Hybrid restorative systems in the clinical point of view are self-cure bulk fill materials laminated with a nano-filled, self-adhesive resin coat. Nowadays, a new glass hybrid innovation called Advanced Glass Hybrid technology was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using prefractive indexes.

Drug: Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)

Resin Modified Glass Ionomer (Fugi II LC, GC, Japan).

ACTIVE COMPARATOR
Drug: Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)

Interventions

Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes

Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)Resin Modified Glass Ionomer (Fugi II LC, GC, Japan).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aging ≥18 years.
  • Patients with High caries risk.
  • Patients with untreated cervical caries lesion that need restorative treatment.
  • Males or females
  • No abnormal occlusion for selected teeth.
  • Patients with good likelihood of recall availability
  • Permanent teeth.
  • Absence of mobility.
  • Primary carious lesions.
  • Vital with positive reaction to thermal stimulus .

You may not qualify if:

  • \. Participants with general/systemic illness. 2. Concomitant participation in another research study. 3. Inability to comply with study procedures. 4. Heavy bruxism habits. 5. Last experience with allergic reactions against any components of the used materials.
  • \. Patients receiving orthodontic treatment. 7. Teeth supporting removable prosthesis 8. Patients with cervical caries lesions that need crown restoration. 9. Xerostomia.
  • Teeth with clinical symptoms of pulpitis such as spontaneous pain or sensitivity to pressure.
  • Non-vital teeth.
  • Periapcal Abscess or Fistula.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

glass ionomer

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
This will be a double blinded study. The participants will not be informed to which group they will be assigned. The operator will be blinded because the restorative procedures for both groups are the same, the outcome assessors will not be informed about the type of restoration they evaluate.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be randomly divided into two groups with a 1:1 allocation using computer generated randomization list (www.random.org).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
masters degree student

Study Record Dates

First Submitted

November 8, 2022

First Posted

November 15, 2022

Study Start

December 1, 2022

Primary Completion

December 1, 2023

Study Completion

December 1, 2023

Last Updated

November 15, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will share

international and national publication

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE